Tracer library / [125I]I-BO530
[125I]I-BO530
- Radionuclide
- I-125 t½ 85666 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- GRPR/PSMA bispecific heterodimer (urea-based PSMA-617 linked to bombesin-based RM26 antagonist)
- Target / mechanism
- Dual targeting of gastrin-releasing peptide receptor (GRPR) and prostate-specific membrane antigen (PSMA) PMID 31340483
- Clinical application
- Theranostics application in prostate cancer PMID 31340483
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC | 69% ± 1% | ≥95% | BO530 | 31340483 2019 Pharmaceutics The heterodimers were radiolabeled with I-125 using Pierce Iodination Reagent (IodoGen) (Thermo Fisher Scientific, Waltham, MA, USA). - radiochemical yields 69% ± 1%, 73% ± 4%, 73% ± 3% for BO530 (Figure 2), BO535, and BO536, respectively |
Need this precursor?We can point you to suppliers for [125I]I-BO530, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 31340483. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.